list : Neuroscience
Stanford Medicine magazine explores the brain and nervous system
The new issue of Stanford Medicine magazine features articles about developments in neuroscience and treatments for conditions affecting the brain and nervous system.
Michelle Monje awarded 'genius grant'
The neuroscientist and pediatric neuro-oncologist is being recognized for her work to understand healthy brain development and create therapies for a group of lethal brain tumors.
Stroke center fills critical care need
Stanford Health Care – ValleyCare's stroke program is recognized for its commitment to meeting rigorous national standards of stroke care.
Karl Deisseroth wins Lasker award
Discoveries by Deisseroth and his two co-recipients regarding microbial light-activated molecules led to his development of a way to manipulate selected neurons in living animals to observe changes in their behavior.
Insulin resistance increases depression risk
About 1 in 3 American adults has insulin resistance, a silent time bomb that doubles their risk for serious depression, Stanford scientists have learned.
With gift, Alzheimer’s center renamed
In addition to supporting the nationally recognized research center, the Good Planet Foundation has endowed a professorship in the Department of Neurology and Neurological Sciences.
Once-nightly narcolepsy drug is effective
A phase 3 study has found that an extended-release version of sodium oxybate reduces daytime sleepiness and attacks of muscle weakness in narcolepsy patients.
A new view of memory’s building blocks
Stanford neuroscientists find that initial memory formation may involve both awareness of our location as well as what we were feeling when we were there.
Endocannabinoids and epilepsy
Release of the brain’s equivalent of THC, marijuana’s active component, reduces seizure activity but leads to post-seizure oxygen deprivation in the brain, Stanford scientists and their collaborators have shown.
Schulman on value of new Alzheimer’s drug
The Food and Drug Administration has approved a new and expensive medication for Alzheimer’s disease, but it’s not clear it helps. Researcher Kevin Schulman discusses what the government should consider before deciding to cover it.